News | September 24, 2012

New Biodegradable Metal Alloy System Patented for Use in Implantable Medical Devices

September 24, 2012 — Bio DG announced that its patent for a novel metal system, to use as biodegradable material in developing implantable medical devices, was granted by the U.S. Patent Office on Aug. 21, 2012. Bio DG's biodegradable alloys are primarily metallic and provide high strength when first implanted, then gradually erode in a predictable and biocompatible manner.

These alloys are engineered to address the limitations of current biodegradable materials such as polymers, as well as non-biodegradable materials such as stainless steel and titanium, that are used in implantable medical devices. Bio DG alloys may be formed into any shape, such as screws, plates, sutures and stents, using common forming techniques, making them ideal for use in a wide range of medical devices across multiple market segments. Agreements are currently in place for this patented technology to be used in the development of products within some key segments.

The alloys are austenitic so that they will not react in a magnetic field, and are formulated from well-tolerated elements so as not to generate a toxic reaction. Bio DG materials have the strength of a steel alloy and are much stronger than a polymer implant.

"The concept of a nonmagnetic biodegradable metal which can be crafted to perform its purpose of coaptation of tissue until fully healed, then eliminated from the body, is a very exciting concept," said Herbert H. Dardik, M.D., chief of vascular surgery at Englewood Hospital in Englewood, N.J. "I can see that this new technology will greatly expand clinical applications where we now limit use of metal sutures and staples, as well as where implants made from polymer technologies are not ideal."

"These alloys have tremendous potential," said Bio DG CEO Herbert R. Radisch, Jr. "Within the orthopedic space they can replace stainless steel and titanium alloy devices meant for temporary or semi-permanent implants. Within the cardiovascular space they can be used to develop strong biodegradable stents that have the ability to degrade over a specific time period. And within the suturing/stapling space, they can be used to develop an implantable surgical staple that does not require a second surgical intervention for removal. Devices made from this patented technology clearly have the potential to improve long-term patient outcomes across a range of therapeutic areas."

Bio DG alloys are engineered to dissolve from the exterior surfaces without compromising the internal structure, thus retaining strength of the remaining undissolved portion of the implant throughout the degradation period. The alloys are non-toxic to the host body. They are ideal for medical devices that must exhibit high strength and are implanted such that removal is not ideal and instead biodegradation is preferred.

For more information: Warren Pelissier, Acom Healthcare Media Relations, 781.749.9290

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Overlay Init